Disease activity return after natalizumab cessation in multiple sclerosis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Disease activity return after natalizumab cessation in multiple sclerosis
Authors
Keywords
-
Journal
Expert Review of Neurotherapeutics
Volume 16, Issue 5, Pages 587-594
Publisher
Informa UK Limited
Online
2016-03-18
DOI
10.1586/14737175.2016.1168295
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation
- (2016) Bianca Weinstock-Guttman et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Anti-JC virus seroprevalence in a Finnish MS cohort
- (2015) M. Kolasa et al. ACTA NEUROLOGICA SCANDINAVICA
- Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis
- (2015) Pietro Iaffaldano et al. BRAIN
- Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads
- (2015) Luca Prosperini et al. Multiple Sclerosis Journal
- Switching from natalizumab to fingolimod
- (2015) Ludwig Kappos et al. NEUROLOGY
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2015) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads
- (2015) Luca Prosperini et al. Multiple Sclerosis Journal
- What to expect after natalizumab cessation in a real-life setting
- (2014) S. Salhofer-Polanyi et al. ACTA NEUROLOGICA SCANDINAVICA
- No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation
- (2014) M. Capobianco et al. EUROPEAN JOURNAL OF NEUROLOGY
- Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients
- (2014) Per Soelberg Sorensen et al. JOURNAL OF NEUROLOGY
- Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE
- (2014) Michael Kaufman et al. JOURNAL OF NEUROLOGY
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study
- (2014) Neda Ebrahimi et al. Multiple Sclerosis Journal
- Fingolimod after natalizumab and the risk of short-term relapse
- (2014) V. G. Jokubaitis et al. NEUROLOGY
- MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study
- (2014) R. J. Fox et al. NEUROLOGY
- Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab
- (2014) Marinella Clerico et al. JAMA Neurology
- Natalizumab Use During the Third Trimester of Pregnancy
- (2014) Aiden Haghikia et al. JAMA Neurology
- Switching From Natalizumab to Fingolimod in Multiple Sclerosis
- (2014) Mikael Cohen et al. JAMA Neurology
- Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients
- (2014) Francesca Sangalli et al. Multiple Sclerosis and Related Disorders
- Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial
- (2013) Claudio Gobbi et al. BMC Neurology
- Predicting PML in natalizumab-treated patients: can we do better?
- (2013) Tobias Derfuss et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Immune surveillance and response to JC virus infection and PML
- (2013) Sarah Beltrami et al. JOURNAL OF NEUROVIROLOGY
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
- (2013) Ralf Gold et al. LANCET
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
- (2013) Patrick Vermersch et al. Multiple Sclerosis Journal
- Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort
- (2013) Tomas Olsson et al. Multiple Sclerosis Journal
- Natalizumab Therapy for Multiple Sclerosis
- (2013) Jens Kuhle et al. SEMINARS IN NEUROLOGY
- Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab
- (2012) S. Rossi et al. EUROPEAN JOURNAL OF NEUROLOGY
- Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis
- (2012) Joachim Havla et al. JOURNAL OF NEUROLOGY
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: clinical and magnetic resonance imaging findings
- (2012) F Rinaldi et al. Multiple Sclerosis Journal
- Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis
- (2012) Anke Vennegoor et al. Multiple Sclerosis Journal
- Lethal multiple sclerosis relapse after natalizumab withdrawal
- (2012) V. Rigau et al. NEUROLOGY
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study
- (2011) María José Magraner et al. JOURNAL OF NEUROLOGY
- De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate
- (2011) Joachim Havla et al. JOURNAL OF NEUROLOGY
- Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients
- (2011) A. Kerbrat et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- (2011) Ludwig Kappos et al. LANCET
- Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment
- (2011) Kerstin Hellwig et al. Multiple Sclerosis Journal
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
- (2011) P. W. O'Connor et al. NEUROLOGY
- Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated
- (2010) Joep Killestein et al. ANNALS OF NEUROLOGY
- Natalizumab dosage suspension: Are we helping or hurting?
- (2010) Timothy W. West et al. ANNALS OF NEUROLOGY
- Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
- (2010) Augusto Miravalle et al. ARCHIVES OF NEUROLOGY
- Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians
- (2010) A. Antonsson et al. JOURNAL OF GENERAL VIROLOGY
- Course of relapsing–remitting multiple sclerosis before, during and after natalizumab
- (2010) Michael D Kaufman et al. Multiple Sclerosis Journal
- Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study
- (2010) F. Sangalli et al. NEUROLOGICAL SCIENCES
- IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AFTER WITHDRAWAL OF NATALIZUMAB?
- (2010) T. Lenhard et al. NEUROLOGY
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells
- (2009) P. Kivisakk et al. NEUROLOGY
- GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study
- (2009) A. D. Goodman et al. NEUROLOGY
- Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
- (2009) B. O. Khatri et al. NEUROLOGY
- Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
- (2008) Amit Bar-Or et al. ANNALS OF NEUROLOGY
- Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
- (2008) O. Stuve et al. NEUROLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started